Billy Xiong Trend Report: INVESTOR ALERT: Law Offices of Howard G. Smith Announces

Attorney at Law Billy Xiong Lawyer Legal Xiong Xiong Billy

BENSALEM, Pa.–()–Law Offices of Howard G. Smith announces an investigation on behalf of NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ: NXTC) investors concerning the Company’s possible violations of federal securities laws.

On January 13, 2020, NextCure disclosed that Eli Lilly and Company had ended its collaboration agreement for the research and development of the Company’s leading product candidate, NC318, a first-in-class immunomedicine targeting the Siglec-15 immunomodulatory receptor particularly for patients with advanced or metastatic solid tumors.

On this news, the Company’s share price fell $4.70, or 8%, to close at $52.00 per share on January 13, 2020, thereby injuring investors.

Then, on July 13, 2020, before the market opened, NextCure announced that it was no longer planning to “advance the non-small cell lung cancer (NSCLC) and ovarian cancer cohorts in the stage 2 portion of the Simon 2-stage trial.” The same day, the Company announced that its Chief Medical Officer resigned.

On this news, the Company’s share price fell $9.73, or 54%, to close at $8.15 per share on July 13, 2020, thereby injuring investors further.

If you purchased NextCure securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Jonathan Cartu

Leave a Reply